NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions and data analytics for clinical research, today announced that UCB has selected the Medidata Clinical Cloud® as its enterprise technology platform.
The Brussels-based global biopharmaceutical company will leverage Medidata’s end-to-end cloud platform to improve operational excellence and better engage patients across UCB’s diverse clinical development portfolio. As part of the multi-year agreement, UCB plans to utilize Medidata’s data management and targeted monitoring capabilities with the goal of improving clinical data quality and availability; and reducing trial costs and cycle times. UCB also plans to leverage Medidata’s mobile health (mHealth) solutions to capture more objective, continuous data in a manner that reduces patient burden and adds value to patient lives.
“UCB is committed to transforming the lives of people with severe diseases, and we are leveraging both scientific advances and cutting-edge technology to do so,” said Tero Laulajainen, Head of Global Clinical Sciences and Operations (GCSO) at UCB. “The Medidata Clinical Cloud will help us get an earlier and more complete view of patients while they undergo therapy, enabling us to explore new models for clinical development and identify insights to drive future innovation.”
In adopting a single, unified platform, UCB will have faster access to clinical data and reduced complexity across its pipeline of neurological and immunological candidates. The global biopharmaceutical company will leverage multiple solutions within the Medidata Clinical Cloud platform, including: Medidata Rave®, Medidata Coder®, Safety Gateway, and Medidata TSDV. UCB plans to use Medidata’s mHealth solution for electronic patient-reported outcomes (ePRO) on a study-by-study basis.
“UCB’s patient-led, science-driven research and development is making a meaningful difference in people’s lives, and Medidata is proud to provide the technology and analytical insights to propel its R&D efforts,” said Mike Capone, Medidata’s chief operating officer. “Medidata’s unified cloud platform is transforming global drug development, and we are uniquely positioned to support the business and innovation goals of UCB and nearly 850 other life sciences customers.”
Connect with Medidata
- Read our blog, Geeks Talk Clinical
- Tweet this: .@UCB_news turns to unified @Medidata #tech to improve clinical #data quality, enhance #patient engagement & more: http://ow.ly/w61j30bb5J3
- Follow us on Twitter: @Medidata
- Find us on LinkedIn
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7,500 people in approximately 40 countries, the company generated revenue of € 4.2 billion in 2016. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.
About Medidata
Medidata is reinventing global drug and medical device development by creating the industry’s leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including nearly 850 global pharmaceutical companies, innovative biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 17 of the world’s top 25 global pharmaceutical companies and is used by 16 of the top 20 medical device developers— from study design and planning through execution, management and reporting.
